Page last updated: 2024-12-07

4-phenylpiracetam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-phenylpiracetam: for the rehabilitation of stroke patients [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132441
CHEMBL ID348639
SCHEMBL ID563022
MeSH IDM0114425

Synonyms (61)

Synonym
4-phenylpiracetam
1-pyrrolidineacetamide, 2-oxo-4-phenyl-
brn 5030440
2-oxo-4-phenyl-1-pyrrolidineacetamide
OPREA1_429090
fonturacetam
fonturacetam [inn]
carphedon
carphedone
karfedon
phenotropil
unii-99qw5ju66y
99qw5ju66y ,
2-(2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide
OPREA1_208829
SDCCGMLS-0035015.P002
smr000109123
MLS000113218
AKOS000519394
CHEMBL348639
2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide
2-(2-oxo-4-phenyl-1-pyrrolidinyl)acetamide
A839108
2-(2-oxidanylidene-4-phenyl-pyrrolidin-1-yl)ethanamide
4-phenyl-2-pyrrolidone-1-acetamide
HMS2183I11
4-phenylpiracetam; carphedon
77472-70-9
phenylpiracetam ,
S5223
(2-oxo-4-phenylpyrrolidin-1-yl)acetamide
rac-2-((4r)-2-oxo-4-phenylpyrolidin-1-yl)acetamide
(r,s)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide
phenotropyl
2-(2-oxo-4-phenyl-pyrrolidin-1-yl)acetamide
fonturacetam [mart.]
4-phenylpiracetam [who-dd]
SCHEMBL563022
CS-1574
HY-14840
AKOS016038810
J-500892
DS-1993
mfcd01456750
EX-A735
F2147-9813
STL511045
phenypiracetam
BCP22034
Q420882
F11808
DTXSID30868438
carphedo
2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide;phenylpiracetam
BBL100068
SB17150
HMS3886K15
AMY38209
CCG-266708
4-phenyl-2-oxopyrrolidine-1-acetamide
P2604

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The pharmacokinetic profiles of R-PhP in mouse plasma and its bioavailability in brain tissue were assessed."( Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice.
Dambrova, M; Grinberga, S; Stelfa, G; Svalbe, B; Vavers, E; Videja, M; Zvejniece, B; Zvejniece, L, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" Active compounds exhibited an inverted U-shaped dose-response curve."( Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
Butler, DE; L'Italien, YJ; Marriott, JG; Nordin, IC; Poschel, PH; Zweisler, L, 1984
)
0.27
"We studied 400 patients with ischemic stroke, including 200 patients (the main group), who received 3 courses of phenotropil in the complex rehabilitation treatment in dosage 400 mg/day during 1 year after stroke."( [Efficacy of phenotropil in the rehabilitation of stroke patients].
Il'iaĭnen, EV; Koval'chuk, IV; Koval'chuk, VV; Melikhova, EV; Skoromets, AA; Stoianova, EG; Vysotskaia, ML, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
importin subunit beta-1 isoform 1Homo sapiens (human)Potency19.95265.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency19.95265.804836.130665.1308AID540263
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID111830Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 2.5 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID111825Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 0.63 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID111826Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 1.25 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID111841Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 5 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID111844Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 80.0 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID111834Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 20.0 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (8.33)18.7374
1990's1 (4.17)18.2507
2000's1 (4.17)29.6817
2010's18 (75.00)24.3611
2020's2 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.03 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (16.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (4.00%)0.25%
Other20 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]